AR069033A1 - Formulaciones inyectables de accion prolongada - Google Patents

Formulaciones inyectables de accion prolongada

Info

Publication number
AR069033A1
AR069033A1 ARP080104654A ARP080104654A AR069033A1 AR 069033 A1 AR069033 A1 AR 069033A1 AR P080104654 A ARP080104654 A AR P080104654A AR P080104654 A ARP080104654 A AR P080104654A AR 069033 A1 AR069033 A1 AR 069033A1
Authority
AR
Argentina
Prior art keywords
poly
mixtures
group
formulation according
glycolide
Prior art date
Application number
ARP080104654A
Other languages
English (en)
Original Assignee
Schering-Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering-Plough Ltd filed Critical Schering-Plough Ltd
Publication of AR069033A1 publication Critical patent/AR069033A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una formulación inyectable líquida de acción prolongada para combatir ectoparásitos y endoparásitos en un animal, que comprende una cantidad terapéuticamente efectiva de al menos una lactona macrocíclica, un solvente que está seleccionado del grupo que consiste en hidrocarburos aromáticos, halocarbonos; tetrahidrofurano, alcohol bencílico, benzoato de bencilo, glicerolformal y mezclas de ellos; y al menos un polímero de poliéster biológicamente aceptable y biodegradable. Reivindicación 2: La formulación de acuerdo con la reivindicación 1, en donde: el polímero de poliéster biológicamente aceptable y biodegradable está seleccionado del grupo que consiste en poli(láctido)s, poli(glicólido)s, poli(láctido(s)-co-glicólido)s, poli(ácido(s)láctico)s, poli(ácido(s) glicólicos)s y poli(ácido(s) láctico(s)-ácido(s) co-glicólico)s, polianhídridos, poliortoésteres, polieterésteres, polietilenglicol, policaprolactona, poliesteramidas, polifosfazinas, policarbonatos, poliamidas, y sus copolímeros y mezclas. Reivindicación 7: La formulación de acuerdo con las reivindicaciones 1 a 6, en donde la lactona macrocíclica está seleccionada del grupo que consiste en abamectina, doramectina, emamectina, eprinomectina, ivermectina, lepimectina y selamectina, milbemectina, milbemicina D, oxima de milbemicina, moxidectina y mezclas de ellas. Reivindicación 12: Uso de una formulación inyectable líquida de acción prolongada de acuerdo con las reivindicaciones 1 a 10 para la preparación de un medicamento para el tratamiento de parasitosis de un animal.
ARP080104654A 2007-10-25 2008-10-24 Formulaciones inyectables de accion prolongada AR069033A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0705822-5A BRPI0705822A2 (pt) 2007-10-25 2007-10-25 formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável
US9501508P 2008-09-08 2008-09-08

Publications (1)

Publication Number Publication Date
AR069033A1 true AR069033A1 (es) 2009-12-23

Family

ID=40297850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104654A AR069033A1 (es) 2007-10-25 2008-10-24 Formulaciones inyectables de accion prolongada

Country Status (9)

Country Link
US (1) US20110039794A1 (es)
EP (1) EP2211839A1 (es)
AR (1) AR069033A1 (es)
AU (1) AU2008316416A1 (es)
BR (2) BRPI0705822A2 (es)
CA (1) CA2702800A1 (es)
MX (1) MX2010004509A (es)
NZ (1) NZ584585A (es)
WO (1) WO2009053466A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852607C (en) * 2011-10-18 2021-05-04 Institut National De La Recherche Agronomique Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
WO2013142152A1 (en) * 2012-03-23 2013-09-26 Regents Of The University Of Minnesota Semi-solid delivery systems
AR094882A1 (es) 2013-02-26 2015-09-02 Zoetis Llc Selamectina para el tratamiento de las infestaciones por piojos de mar, composición
IL298259B1 (en) * 2020-05-20 2024-08-01 Intervet Int Bv Injectable pharmaceutical compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0873127B1 (en) * 1995-09-25 2006-11-15 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
ES2359973T3 (es) * 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
BRPI9908893B8 (pt) * 1998-03-19 2021-05-25 Merck & Co Inc composição polimérica líquida para a liberação controlada de substâncias bioativas hidrofóbicas.
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
GB2386067A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species
AU2003275509A1 (en) * 2003-05-25 2004-12-13 Eco Animal Health Ltd. Dimeticone-containing sustained formulation
US8362086B2 (en) * 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations

Also Published As

Publication number Publication date
MX2010004509A (es) 2010-05-03
BRPI0705822A2 (pt) 2009-06-23
CA2702800A1 (en) 2009-04-30
NZ584585A (en) 2012-08-31
BRPI0818258A2 (pt) 2019-09-24
WO2009053466A1 (en) 2009-04-30
US20110039794A1 (en) 2011-02-17
AU2008316416A1 (en) 2009-04-30
EP2211839A1 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
ES2477993T3 (es) Matriz de polímero insoluble en agua para el suministro de fármaco
KR102536696B1 (ko) 향상된 투과성을 가지는 약물학적 조성물
AR069033A1 (es) Formulaciones inyectables de accion prolongada
EP3479818A1 (en) Long acting injectable parasiticidal formulations
ES2659159T3 (es) Formulaciones de moxidectina inyectable de acción prolongada y nuevas formas cristalinas de moxidectina
IL262750A (en) Epinephrine preparations with increased administration
EP4218724A3 (en) Microstructure array for delivery of active agents
EP1339389A4 (en) COMPOSITION FOR THE PROLONGED RELEASE OF M HYDROPHOBIC DRUGS, AND CORRESPONDING LABORATION PROCESS
AR113096A1 (es) Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
AR083787A1 (es) Composicion farmaceutica que comprende un inhibidor del transportador 2 de sodio-glucosa (sglt2) y una insulina, procedimientos de tratamiento y usos de la misma
CA2518791A1 (en) Formulations for cell-schedule dependent anticancer agents
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
PE20001319A1 (es) Formulaciones antiparasitarias de avermectinas o milbemicinas
AR075846A1 (es) Sistema de administracion de farmaco de lactona macrociclica.uso. metodo de tratamiento
RU2010126173A (ru) Системы растворителей для жидких наружных композиций для борьбы с паразитами
CY1114311T1 (el) Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης
EP3687509A1 (en) Pharmaceutical compositions with enhanced permeation
UY29342A1 (es) Composicione antihelmintica
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
ES2950392T3 (es) Espumas de elución de fármacos y producción de las mismas
AR033918A1 (es) Composicion para acelerar la soldadura de una fractura osea
AR061655A1 (es) Composicion de microesferas polimericas degradables
US11273131B2 (en) Pharmaceutical compositions with enhanced permeation
ES2390224T3 (es) Composición parasiticida
RU2012150080A (ru) Фармацевтическая композиция из полимерных микрочастиц с модификационной кинетикой высвобождения плохорастворимых лекарственных веществ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal